Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Zhejiang Huahai Pharmaceutical Co Ltd's Drug Receives Approval from FDA


Wednesday, 23 Jan 2013 07:00pm EST 

Zhejiang Huahai Pharmaceutical Co Ltd announced that a kind of lamotrigine extended-release tablets, which is used for epilepsy, developed by Par Pharmaceutical and produced by the Company, received the approval from Foods and Drug Administration on January 19, 2013 and has been on sale in the United States since the same day. 

Company Quote

11.86
0.06 +0.51%
16 Apr 2014